Hengrui’s PD-1 Camrelizumab Moves Step Closer To US Filing

Positive outcomes from a multiregional Phase III trial provide Jiangsu Hengrui Medicine with a milestone in the Chinese firm's quest for globalization, as it looks to succeed where others have had recent setbacks.